PFE vs RVTY vs TMO Stock Comparison

Pfizer, Revvity and Thermo Fisher Scientific Prices as of Nov 13, 2026 Peers: Industry group
PFE Pfizer Inc
$28.90 -1.1% 1M +12.1% 1Y
Market cap
$165.02B
P/E
40.9x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
6 wins
RVTY Revvity, Inc.
$154.52 +1.5% 1M +65.4% 1Y
Market cap
$16.69B
P/E
65.9x
Revenue (TTM)
$2.94B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win

Head to Head

12 decided of 12

Pfizer leads on 6 of the 12 questions below (Pfizer 6, Thermo Fisher Scientific 5, Revvity 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPFERVTYTMOLeader
Larger companyMarket capitalisation $165.02B $16.69B $257.27B TMO
Cheaper on earningsLower P/E, profitable companies only 40.9x 65.9x 36.4x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 9.8x 29.9x 27.0x PFE
Faster revenue growthRevenue growth, trailing twelve months +1.3% +4.6% +8.3% TMO
More profitableNet margin, trailing twelve months 6.3% 8.6% 14.9% TMO
Better return on capitalReturn on invested capital 12.3% 3.3% 8.0% PFE
Less leveragedLower net debt / EBITDA 1.9x 2.6x 3.1x PFE
Higher dividend yieldTrailing dividend yield 0.06% 0.00% 0.00% PFE
Better 1-year returnPrice return, last 12 months +12.1% +65.4% +20.7% RVTY
Better 5-year returnAnnualised price return, 5 years -10.3%/yr -3.4%/yr +2.0%/yr TMO
Less volatileAnnualised volatility, 1 year 21.7% 41.2% 30.7% PFE
Higher overall scoreMean of the five percentile scores vs peers 68/100 61/100 60/100 PFE

Percentile Scorecard

PFERVTYTMO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPFERVTYTMO
Valuation 95 #37 of 660 72 #70 of 243 62 #94 of 243
Growth 37 #392 of 619 38 #141 of 228 41 #136 of 228
Profitability 92 #50 of 595 81 #43 of 222 82 #40 of 222
Financial Health 25 #516 of 683 56 #110 of 248 31 #172 of 248
Shareholder Returns 91 #44 of 459 56 #70 of 158 82 #29 of 158
Overall 68 61 60
  • PFE ranked among 695 companies in Pharmaceuticals and Biotechnology
  • RVTY ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPFERVTYTMOSPY
1 month -1.1%+1.5%+4.0% -2.0%
3 months +7.9%+32.2%+19.1% -2.8%
6 months +14.1%+64.4%+59.7% +2.0%
Year to date +16.1%+59.7%+20.8% +10.6%
1 year +12.1%+65.4%+20.7% +12.2%
3 years -1.2%+75.9%+52.5% +68.1%
3 years, per year -0.4%+20.7%+15.1% +18.9%
5 years -41.9%-15.8%+10.2% +61.4%
5 years, per year -10.3%-3.4%+2.0% +10.1%
10 years -11.3%+203.6%+362.9% +248.5%
10 years, per year -1.2%+11.7%+16.6% +13.3%

Risk

MeasurePFERVTYTMOSPY
Volatility, 1Y 21.7%41.2%30.7% 13.6%
Downside volatility, 1Y 21.9%37.1%29.2% 13.9%
Beta vs S&P 500, 1Y 0.261.220.71 1.00
Return / volatility, 1Y 0.561.590.67 0.90
Max drawdown, 5Y -64.8%-59.2%-41.5% -25.4%
From 52-week high -6.1%-6.8%-3.0% -3.2%
52-week high $30.79$165.78$721.63 $779.14
52-week low $23.67$82.26$438.34 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePFERVTYTMO
P/E now vs peer median 40.8xmedian 17.0x 68.1xmedian 26.5x 36.6xmedian 26.5x
P/S now vs peer median 2.6xmedian 8.4x 5.9xmedian 2.7x 5.5xmedian 2.7x
EV/EBITDA now vs peer median 8.2xmedian 14.6x 24.4xmedian 18.4x 25.5xmedian 18.4x
P/FCF now vs peer median 14.0xmedian 19.0x 28.7xmedian 25.4x 34.2xmedian 25.4x
P/B now vs peer median 1.8xmedian 2.0x 2.4xmedian 2.5x 4.7xmedian 2.5x
PEG now vs peer median -1.47median 0.43 -2.46median 0.98 4.84median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPFERVTYTMO
Revenue $63.63B $2.94B $47.35B
Gross profit $46.69B $1.64B $19.45B
Operating income $19.40B $372.09M $8.47B
Net income $4.06B $253.20M $7.09B
Free cash flow $11.79B $601.13M $7.60B
R&D $11.52B $213.15M $1.40B
EPS (diluted) $0.70 $2.26 $19.06
Cash & equivalents $1.82B $592.80M $5.46B
Total debt $62.67B $2.63B $41.37B
Shares (diluted) 5.75B 111.83M 371.00M
Enterprise value $112.37B $13.29B $233.79B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPFERVTYTMO
P/E 40.8x 68.1x 36.6x
P/FCF 14.0x 28.7x 34.2x
P/Operating cash flow 11.6x 25.9x 27.8x
P/S 2.6x 5.9x 5.5x
P/B 1.8x 2.4x 4.7x
P/Tangible book 3.8x 3.4x 7.1x
EV/EBITDA 8.2x 24.4x 25.5x
EV/EBIT 11.0x 51.8x 34.8x
EV/Revenue 3.3x 6.6x 6.2x
EV/FCF 18.1x 32.1x 38.8x
EV/Operating cash flow 15.0x 28.9x 31.6x
PEG (3Y EPS CAGR) -1.47 -2.46 4.84

Growth

14 metrics
MetricPFERVTYTMO
Revenue growth (1Y) 1.3% 4.6% 8.3%
Revenue CAGR (3Y) -3.2% 1.7% 2.9%
Gross profit growth (1Y) 1.3% 5.8% 7.8%
Gross profit CAGR (3Y) 2.7% 1.2% 4.0%
Operating income growth (1Y) -4.3% 2.3% 12.8%
Operating income CAGR (3Y) 7.4% 1.0% 7.2%
Net income growth (1Y) -58.9% 6.6% 7.9%
Net income CAGR (3Y) -27.2% -30.1% 6.2%
EPS growth (1Y) -59.2% 10.1% 9.7%
EPS CAGR (3Y) -27.7% -27.6% 7.6%
Operating cash flow growth (1Y) 8.4% 14.4% 21.9%
Operating cash flow CAGR (3Y) 5.6% 49.3% 4.5%
Free cash flow growth (1Y) 13.6% 19.1% 24.3%
Free cash flow CAGR (3Y) 13.0% 44.7% 5.1%

Profitability

14 metrics
MetricPFERVTYTMO
Gross margin 73.4% 55.9% 41.1%
EBITDA margin 40.7% 26.8% 24.4%
Operating margin 30.5% 12.6% 17.9%
Pretax margin 6.7% 9.6% 16.7%
Net margin 6.3% 8.6% 14.9%
FCF margin 18.5% 20.4% 16.0%
Operating cash flow margin 22.3% 22.7% 19.7%
Return on equity 4.7% 3.5% 13.2%
Return on assets 2.0% 2.2% 6.2%
Return on invested capital 12.3% 3.3% 8.0%
Return on capital employed 11.3% 3.4% 8.5%
Asset turnover 0.3x 0.2x 0.4x
Cash conversion (OCF / net income) 3.5x 2.6x 1.3x
Stock comp / revenue 1.7% 0.9% 0.7%

Financial Health

11 metrics
MetricPFERVTYTMO
Debt / assets 30.6% 22.9% 36.2%
Debt / equity 0.7x 0.4x 0.8x
Net debt / EBITDA 1.9x 2.6x 3.1x
Debt / FCF 5.3x 4.4x 5.4x
Liabilities / assets 56.4% 36.7% 52.1%
Equity / assets 43.6% 63.3% 47.9%
Interest coverage – 4.2x 12.0x
Current ratio 1.4x 2.7x 1.8x
Quick ratio 0.9x 1.9x 1.2x
Cash ratio 0.4x 0.8x 0.4x
Altman Z-score 2.34 3.69 4.18

Shareholder Returns

7 metrics
MetricPFERVTYTMO
Dividend yield 6.0% 0.2% 0.3%
Net buyback yield – 1.5% 1.6%
Shareholder yield 6.0% 1.7% 1.8%
Payout ratio (earnings) 241.2% 12.4% 9.5%
Payout ratio (FCF) 83.1% 5.2% 8.9%
Dividend growth (1Y) 0.9% -5.9% 8.0%
Dividend CAGR (3Y) 2.2% -6.2% 10.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPFERVTYTMO
Forward P/E 9.8xFY2026 29.9xFY2026 27.0xFY2026
EPS, next fiscal year $2.95FY2026 $5.16FY2026 $25.92FY2026
EPS growth, next FY -8.4%FY2026 +2.0%FY2026 +13.3%FY2026
EPS growth, the year after -5.8% +11.0% +2.2%
Revenue, next fiscal year $61.46BFY2026 $3.00BFY2026 $50.12BFY2026
Revenue growth, next FY -1.8%FY2026 +4.8%FY2026 +12.5%FY2026
Revenue growth, the year after +4.0% -2.0% -2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPFERVTYTMO
Held by institutions 66.9% 100.0% 90.2%
Institutions holding 2,842 547 2,627
Change in shares held, QoQ +2.0% -1.3% +0.8%
Institutions buying 1,327 303 1,145
Institutions selling 1,206 161 1,145
Buyers to sellers 1.10 1.88 1.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PFERVTYTMO
PFE 1.00 0.15 0.24
RVTY 0.15 1.00 0.72
TMO 0.24 0.72 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PFE, RVTY and TMO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Pfizer (PFE) $165.02B, Revvity (RVTY) $16.69B, Thermo Fisher Scientific (TMO) $257.27B.

Which stock is cheaper, PFE, RVTY and TMO?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Pfizer (PFE) 40.9x, Revvity (RVTY) 65.9x, Thermo Fisher Scientific (TMO) 36.4x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Pfizer (PFE) 9.8x, Revvity (RVTY) 29.9x, Thermo Fisher Scientific (TMO) 27.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Pfizer (PFE) +1.3%, Revvity (RVTY) +4.6%, Thermo Fisher Scientific (TMO) +8.3%.

Which company is more profitable?

Thermo Fisher Scientific (TMO) has the highest net margin (Pfizer (PFE) 6.3%, Revvity (RVTY) 8.6%, Thermo Fisher Scientific (TMO) 14.9%). On return on invested capital, Pfizer (PFE) leads (Pfizer (PFE) 12.3%, Revvity (RVTY) 3.3%, Thermo Fisher Scientific (TMO) 8.0%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Pfizer (PFE) +12.1%, Revvity (RVTY) +65.4%, Thermo Fisher Scientific (TMO) +20.7%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Pfizer (PFE) -10.3%/yr, Revvity (RVTY) -3.4%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Pfizer (PFE) has the highest dividend yield: Pfizer (PFE) 0.06%, Revvity (RVTY) 0.00%, Thermo Fisher Scientific (TMO) 0.00%.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Pfizer (PFE) 21.7%, Revvity (RVTY) 41.2%, Thermo Fisher Scientific (TMO) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PFE, RVTY and TMO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Pfizer (PFE) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.